LEADER 05894nam 22007454a 450 001 9910450176503321 005 20200520144314.0 010 $a1-281-12625-X 010 $a9786611126254 010 $a0-8144-2859-2 035 $a(CKB)1000000000031430 035 $a(OCoLC)614665643 035 $a(CaPaEBR)ebrary10075614 035 $a(SSID)ssj0000172995 035 $a(PQKBManifestationID)11168325 035 $a(PQKBTitleCode)TC0000172995 035 $a(PQKBWorkID)10163134 035 $a(PQKB)11149342 035 $a(MiAaPQ)EBC3001805 035 $a(Au-PeEL)EBL3001805 035 $a(CaPaEBR)ebr10075614 035 $a(CaONFJC)MIL112625 035 $a(OCoLC)748521033 035 $a(EXLCZ)991000000000031430 100 $a20040922d2005 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aHope or hype$b[electronic resource] $ethe obsession with medical advances and the high cost of false promises /$fRichard A. Deyo, Donald L. Patrick 210 $aNew York $cAMACOM, American Management Association$dc2005 215 $a1 online resource (352 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-8144-0845-1 320 $aIncludes bibliographical references (p. [291]-326) and index. 327 $aCan there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Ineffective. inferior or needlessly costly new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. 327 $aCan there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Useless, harmful, or marginal: popular treatments that caused unnecessary disability, dollar costs, or death -- Ineffective or inferior new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- Crossing the threshold: improving the transition from "experimental" to "standard care" -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. 606 $aMedical innovations$zUnited States$xEvaluation 606 $aMedical technology$zUnited States$xEvaluation 606 $aMedical care$xTechnological innovations$zUnited States$xEvaluation 606 $aMedical care$zUnited States$xEvaluation 606 $aMedical innovations$xEconomic aspects$zUnited States 606 $aMedical technology$zUnited States$xCost effectiveness 606 $aMedical care$xTechnological innovations$zUnited States$xCost effectiveness 606 $aMedical care, Cost of$zUnited States 608 $aElectronic books. 615 0$aMedical innovations$xEvaluation. 615 0$aMedical technology$xEvaluation. 615 0$aMedical care$xTechnological innovations$xEvaluation. 615 0$aMedical care$xEvaluation. 615 0$aMedical innovations$xEconomic aspects 615 0$aMedical technology$xCost effectiveness. 615 0$aMedical care$xTechnological innovations$xCost effectiveness. 615 0$aMedical care, Cost of 676 $a610/.28 700 $aDeyo$b Richard A$0896061 701 $aPatrick$b Donald L$0896062 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910450176503321 996 $aHope or hype$92001740 997 $aUNINA